LLY Jun 2024 290.000 put
| Previous close | 0.0700 |
| Open | 2.1700 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 290.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.0500 - 0.0700 |
| Contract range | N/A |
| Volume | |
| Open interest | 135 |
- Yahoo Finance Video
Why these analysts are bullish on healthcare stocks
The healthcare sector has underperformed throughout 2024, but as the first quarter earnings season unfolds, Jefferies Healthcare Services Equity Research Analyst Brian Tanquilut and Grey Ghost Advisors Private Equity Investor Meghan Fitzgerald join Market Domination to discuss how investors should position themselves in this market. Fitzgerald remains bullish on the healthcare sector, believing it still has "a lot of long and important tailwinds." She cites the sector's historical outperformance during market downturns and election years as reasons for her optimism. Fitzgerald anticipates strong earnings from companies with GLP-1 drug portfolios this week, describing it as an "easy beat." Tanquilut notes a "rise in broader healthcare utilization trends," which is now reflected in healthcare insurers' earnings. While there has been weakness in this area, he highlights the "strength in volume" from healthcare providers. However, Tanquilut acknowledges that with consumer spending slowing, consumer-focused healthcare segments, such as drugstores, have experienced pressure. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. Editor's note: This article was written by Angel Smith
Yahoo FinanceHow expanded use of GLP-1s could affect long-term outlooks for Eli Lilly and Novo Nordisk
The latest GLP-1 drugs are starting to see proof of greater use beyond diabetes and obesity. How will it affect makers Novo Nordisk and Eli Lilly?
- Reuters
US STOCKS-Wall St set to open lower on economic data; Fed verdict on tap
U.S. stocks were poised for a lower open on Tuesday as stronger-than-expected labor costs signaled persistent inflationary pressures, while caution prevailed ahead of the Federal Reserve's interest rate decision. Money markets are largely expecting the U.S. central bank to stand pat on interest rates this meeting, while pricing in just about 31 basis points (bps) of rate cuts this year, down from about 150 bps estimated at the start of 2024, according to LSEG data. "This pretty much tells you that the Fed is going to be very reluctant to reduce short-term interest rates in 2024 and that's had the predictable impact on the stock market," said Hugh Johnson, chief economist at Hugh Johnson Economics.
